Paper Details 
Original Abstract of the Article :
Cardiovascular side effects of broadly used chemotherapeutic drugs such as Tamoxifen citrate (TC), Capecitabine (CP) and Epirubicin (EP) among cancer survivors are well established. Nitric oxide (NO) is known to protect cardiovascular tissues under conditions of stress. NO can act through cyclic gua...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/1440-1681.13181

データ提供:米国国立医学図書館(NLM)

Breast Cancer Drugs: A Double-Edged Sword for Vascular Health

This research investigates the potential impact of widely used breast cancer drugs on the fundamental vascular functions of endothelial cells, the cells lining blood vessels. The study reveals that these drugs can disrupt protein S-nitrosylation, a vital process involved in maintaining vascular health.

The Unintended Consequences of Breast Cancer Drugs

This research explores the potential cardiovascular side effects of commonly used breast cancer drugs, revealing their ability to disrupt protein S-nitrosylation, a critical process for maintaining vascular health. The findings highlight the need for careful monitoring and potential management strategies to mitigate these risks.

The Balancing Act of Cancer Treatment and Vascular Health

Imagine the body as a vast desert landscape, where the delicate balance between cancer treatment and vascular health is a constant challenge. This research investigates the potential impact of breast cancer drugs on vascular functions, shedding light on the importance of carefully managing these drugs to minimize potential cardiovascular complications.

Dr.Camel's Conclusion

This study reveals the potential of breast cancer drugs to disrupt protein S-nitrosylation, a vital process for maintaining vascular health. The findings highlight the need for careful monitoring and potential management strategies to mitigate these risks and ensure the well-being of cancer survivors.
Date :
  1. Date Completed 2021-05-03
  2. Date Revised 2021-05-03
Further Info :

Pubmed ID

31549415

DOI: Digital Object Identifier

10.1111/1440-1681.13181

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.